(Q35003623)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761412%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

review article

1 reference

title

Neridronic acid for the treatment of bone metabolic diseases (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761412%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761412%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Luca Idolazzi

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761412%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

5

Silvano Adami

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761412%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

author name string

Ombretta Viapiana

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761412%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Elena Fracassi

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761412%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

language of work or name

English

0 references

publication date

1 October 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761412%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Metabolism & Toxicology

7 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761412%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

volume

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761412%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761412%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

page(s)

1305-1311

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761412%20AND%20SRC:MED&resulttype=core&format=json

Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite

7 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425250903029190

Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903029190

Neridronate and human osteoblasts in normal, osteoporotic and osteoarthritic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903029190

Anti-tumour activity of zoledronic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903029190

Cyclic administration of pamidronate in children with severe osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903029190

Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903029190

Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903029190

Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903029190

Early bisphosphonate treatment in infants with severe osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903029190

Intravenous neridronate in adults with osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903029190

Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903029190

Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903029190

Effects of neridronate treatment in elderly women with osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903029190

Intramuscular neridronate in postmenopausal women with low bone mineral density.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903029190

Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903029190

Preventing bone loss during androgen deprivation therapy for prostate cancer: early experience with neridronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903029190

Bisphosphonate therapy of reflex sympathetic dystrophy syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903029190

Combined effect of Neridronate and specific antibiotic therapy in a case of tuberculous spondylodiscitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903029190

Single infusion of neridronate (6-amino-1-hydroxyhexylidene-1,1-bisphosphonate) in patients with active rheumatoid arthritis: effects on disease activity and bone resorption markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903029190

Treatment of malignant hypercalcaemia with aminohexane bisphosphonate (neridronate).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903029190

Osteonecrosis of the jaw and the role of bisphosphonates: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903029190

Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903029190

Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903029190

Intravenous Neridronate in Children With Osteogenesis Imperfecta: A Randomized Controlled Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903029190

Intravenous intermittent neridronate in the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903029190

10.1517/17425250903029190

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761412%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference